Agree. The question is - is it a long term trend or a more shorter term impact due to the FDA overhang in the market.
Axrion market share only dropped .1% and prescription value was flat (i assume that is before rebating)... my rough cals suggest .1% = c. $2.3m in gross sales in the US market... so that doesn't really add up to the drop.
I think the net sales result could have been impacted by increased rebating (to get to the reported net sales figures) but ACR did not provide much insight into that...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(5.26%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $11.58K | 619.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 335415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 516258 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |